Kronos Bio, Inc.
KRON · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $3 |
| % Growth | -17.9% | -4.2% | -11.8% | – |
| Cost of Goods Sold | $0 | $2 | $0 | $0 |
| Gross Profit | $2 | $2 | $2 | $3 |
| % Margin | 81.3% | 100% | 100% | 100% |
| R&D Expenses | $2 | $8 | $12 | $14 |
| G&A Expenses | $6 | $5 | $6 | $6 |
| SG&A Expenses | $6 | $5 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $16 | $0 | $1 |
| Operating Expenses | $8 | $29 | $18 | $21 |
| Operating Income | -$9 | -$27 | -$16 | -$18 |
| % Margin | -506.5% | -1,196.2% | -663.1% | -670.5% |
| Other Income/Exp. Net | $1 | $1 | $2 | $2 |
| Pre-Tax Income | -$8 | -$26 | -$14 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$26 | -$14 | -$16 |
| % Margin | -448.7% | -1,137.1% | -595.3% | -602.7% |
| EPS | -0.14 | -0.43 | -0.23 | -0.27 |
| % Growth | 67.4% | -87% | 14.8% | – |
| EPS Diluted | -0.14 | -0.43 | -0.23 | -0.27 |
| Weighted Avg Shares Out | 61 | 60 | 60 | 60 |
| Weighted Avg Shares Out Dil | 61 | 60 | 60 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$11 | -$15 | -$17 |
| % Margin | -330.2% | -469.3% | -645.7% | -633.4% |